集团亮点

Business Update

陈刚韦韬会见医渡科技董事长宫如璟

Chen Gang and Wei Tao Meet with Yidu Tech Chairlady Gong Rujing

广西壮族自治区党委书记、自治区人大常委会主任陈刚，自治区主席韦韬在南宁会见了医渡科技创始人兼董事长宫如璟，联合创始人兼 CEO 徐济铭一行。双方就加强人工智能医疗领域合作、共同开拓东盟市场等议题进行了深入交流。陈刚表示，广西正积极构建"北上广研发+广西集成+东盟应用"的发展路径，加快人工智能在医疗卫生等领域的创新应用。他希望医渡科技扎根广西，参与中国—东盟人工智能创新合作中心和防城港国际医学开放试验区建设，推动人工智能与医疗卫生、健康管理等深度融合。宫如璟介绍了企业与广西的合作计划，表示医渡科技将充分发挥自身优势，以广西为枢纽推进面向东盟的医疗人工智能合作，构建医疗人工智能跨境产业生态，助力广西经济社会高质量发展。

Chen Gang, Secretary of the Communist Party of China (CPC) Committee of the Guangxi Zhuang Autonomous Region and Chairman of the Regional People's Congress Standing Committee, together with Wei Tao, Chairman of the Guangxi Zhuang Autonomous Region, met in Nanning with Gong Rujing, Founder and Chairlady of Yidu Tech, and Xu Jiming, Co-founder and CEO.

Both parties held in-depth discussions on strengthening cooperation in the field of artificial intelligence in healthcare and jointly exploring the ASEAN market. Chen Gang stated that Guangxi is actively building a development path of "R&D in Beijing,

Shanghai and Guangzhou + integration in Guangxi + application in ASEAN," accelerating innovative applications of artificial intelligence in healthcare and related fields. He expressed hope that Yidu Tech would establish a strong presence in Guangxi, participate in the construction of the China-ASEAN AI Innovation Cooperation Center and the Fangchenggang International Medical Open Experimental Zone, and promote deep integration of artificial intelligence with healthcare and health management.

Gong Rujing introduced the company's cooperation plans with Guangxi, stating that Yidu Tech will leverage its strengths to use Guangxi as a hub for advancing AI medical cooperation targeting ASEAN, building a cross-border AI medical industry ecosystem, and contributing to Guangxi's high-quality economic and social development.

宫如璟受邀出席 2025 天下女人国际论坛

Gong Rujing Invited to Attend 2025 Her Village International Forum

在 2025 天下女人国际论坛上，医渡科技创始人、董事长宫如璟分享了对医疗 AI 发展的深刻见解。她指出，尽管目前医疗 AI 仍面临算法偏见与数据准确性等挑战，但相关技术已在多家医院投入实际应用，有效提升了诊疗效率并降低医疗成本。宫如璟强调，AI 不会取代人类，但善于运用 AI 技术的人将走在时代前沿。她特别提到，AI 技术的持续迭代与发展，将为医疗行业创造新的市场需求和就业机会，对女性从业者而言尤其意味着重要的中长期发展机遇。

作为女性创业者，宫如璟认为女性对生命体验的深刻理解，所带来的同理心与韧性，成为在医疗科技领域的独特优势。她呼吁更多女性积极拥抱和学习 AI 技术，共同参与塑造医疗行业的未来。

At the 2025 Her Village International Forum, Gong Rujing, Founder and Chairlady of Yidu Tech, shared profound insights on the development of AI medical. She pointed out that although AI medical still faces challenges such as algorithmic bias and data accuracy, related technologies have already been deployed in multiple hospitals, effectively improving diagnostic efficiency and reducing healthcare costs. Gong

emphasized that AI will not replace humans, but those who know how to leverage AI will stand at the forefront of the times. She highlighted that the continuous iteration and advancement of AI technology will create new market demands and job opportunities in the healthcare sector, which represents particularly important medium- to long-term development opportunities for women professionals.

As a female entrepreneur, Gong believes that women's deep understanding of life experiences, combined with their empathy and resilience, provides them with unique advantages in the field of medical technology. She called on more women to actively embrace and learn AI technology, and to participate together in shaping the future of the healthcare industry.

宫如璟联合署名文章在世界经济论坛发表

Gong Rujing's Co-authored Article Published by World Economic Forum

世界经济论坛官网发布了文莱卫生部部长穆罕默德·伊山姆·贾法尔与医渡科技创始人、董事长宫如璟联合署名文章"How Brunei's BruHealth journey charts the future

of digital health"（《文莱 BruHealth：勾勒数字健康未来》）。文章深刻剖析了 BruHealth 这一平台如何从危机应对工具，成功蜕变为支撑文莱全民健康体系的数字基础设施，其"循序渐进、用户驱动"的开发策略、创新的激励机制以及 AI 赋能的健康管理，为全球数字健康的可持续转型提供了新范式。文莱经验表明，数字健康转型的核心在于技术创新、普惠可及与治理能力的协同发展。

BruHealth 由医渡科技与文莱卫生部合力打造，宫如璟在文章中指出，医渡科技将基于 BruHealth 平台建设经验，进一步推动精准公共卫生、数字疗法和 AI 健康洞察等前沿应用。在提升技术先进性的同时，始终关注可及性，确保技术进步真正普惠大众、创造价值。

The official website of World Economic Forum published a co-authored article by Brunei's Minister of Health, Mohammad Isham Jaafar, and Gong Rujing, founder and chairlady of Yidu Tech, titled "How Brunei's BruHealth journey charts the future of digital health." The article provides an in-depth analysis of how BruHealth evolved from a crisis-response tool into the digital infrastructure underpinning Brunei's universal health system. Its "progressive, user-driven" development strategy, innovative incentive mechanisms, and AI-enabled health management have created a new paradigm for the sustainable transformation of global digital health. The Brunei experience shows that the core of digital health transformation lies in the coordinated development of technological innovation, universal accessibility, and governance capacity.

BruHealth was jointly developed by Yidu Tech and Brunei's Ministry of Health. In the article, Gong Rujing pointed out that Yidu Tech will build on the experience of developing the BruHealth platform to further advance cutting-edge applications such as precision public health, digital therapeutics, and AI-driven health insights. While enhancing technological sophistication, the company remains focused on accessibility, ensuring that technological progress truly benefits the public and creates value.

WORLD ECONOMIC FORUM

Join us   Sign in

HEALTH AND HEALTHCARE SYSTEMS

How Brunei's BruHealth journey charts the future of digital health

Jul 22, 2025

医渡科技受邀出席"相约湾区·未来产业论坛"

Yidu Tech Invited to Attend the "InnoBay·Future Industry Forum"

由深圳清华大学研究院与粤港澳大湾区国家技术创新中心国际总部联合主办的人工智能产业创新生态沙龙在深圳成功举办。医渡科技公共事务副总裁唐鹤受邀出席本次活动，并在"智引全球：AI 企业出海的机遇与挑战"主题沙龙中，结合医渡科技在医疗人工智能领域的技术积累与国际拓展经验，分享了公司在全球市场布局、技术标准对接及跨境合规等方面的实践心得，展现了医渡科技在国际化发展中的创新成果与战略布局。

The Artificial Intelligence Industry Innovation Ecosystem Salon, co-hosted by the Research Institute of Tsinghua University in Shenzhen and the International Headquarters of Greater Bay Area National Center of Technology Innovation, was successfully held in Shenzhen. Tang He, Vice President of Public Affairs at Yidu Tech, was invited to attend the event and spoke at the AI Companies Global Expansion Session. Drawing on Yidu Tech's technological expertise in AI medical and its international expansion experience, she shared the company's insights on global market strategy, alignment with international technical standards, and cross-border

compliance. Her remarks highlighted Yidu Tech's innovative achievements and strategic initiatives in driving its international development.

业务进展

Business Progress

医渡科技大模型首次赋能医美，携手广附院推出"美易智能体"

Yidu Tech's LLM Empowers Medical Aesthetics, Launches "Meiyi Intelligent Agent" with Affiliated Hospital of Guangdong Medical University

医渡科技与广东医科大学附属医院（简称"广附院"）联合打造的"脉管性疾病多模态专病数据库""美易智能体"在广东省医院协会整形美容专业委员会 2025 年学术年会上正式发布。这不仅是医渡科技大模型首次应用于医美领域，也标志着国内整形美容领域在数据整合与智能应用方面取得重要进展。

At the 2025 Academic Annual Meeting of the Plastic Surgery Committee of the Guangdong Hospital Association, Yidu Tech and the Affiliated Hospital of Guangdong Medical University jointly unveiled the "Vascular Disease Multimodal Specialty Database" and the "Meiyi Intelligent Agent." This marks the first application of Yidu Tech's large language model in the field of medical aesthetics and signifies an important advancement in data integration and intelligent applications within China's plastic surgery and aesthetic medicine sector.

医渡科技数字疗法海南落地成效公布

Yidu Tech Announces Outcomes of Digital Therapeutics Deployment in Hainan

在 2025 数字疗法大会"AI+慢病管理场景应用论坛"上，医渡科技医患智能与数字化业务线副总裁李羽涵分享数字疗法在基层糖尿病管理的实践与成效。医渡科技深度参与海南"2+3"健康服务包项目，与首批试点地区陵水紧密合作，目前陵水 99.09%的在管患者已纳入系统化照护，空腹血糖达标率、糖化血红蛋白达标率从基线水平提升 18.63%和 4.68%，显著高于全省平均水平，为基层糖尿病管理树立了成功典范。公司持续深化海南战略布局，已将 AI 医疗创新成果逐步辐射至三亚、万宁、琼海、文昌等重要城市，并进一步拓展高血压等更多慢性病种的数字疗法服务，推动区域医疗服务能力全面升级。按照规划，2025 年内公司将实现对超过 10 万区域患者的覆盖管理，为提升居民健康水平注入强劲动能。

At the "AI + Chronic Disease Management Applications Forum" during the 2025 Digital Therapeutics Conference, Li Yuhan, VP of Yidu Tech's Intelligent and Digital Business Division, shared the company's practices and outcomes in applying digital therapeutics to primary-level diabetes management. Yidu Tech has been deeply involved in

Hainan's "2+3" Health Service Package project, working closely with the first pilot region, Lingshui. To date, 99.09% of patients under management in Lingshui have been incorporated into systematic care. The rates of achieving targets for fasting blood glucose and HbA1c have improved by 18.63% and 4.68% from baseline, significantly outperforming the provincial average—establishing a successful model for primary-level diabetes management.

The company is steadily advancing its strategic presence in Hainan, extending AI-driven medical innovations to key cities including Sanya, Wanning, Qionghai, and Wenchang. It is also expanding digital therapeutics services to additional chronic conditions such as hypertension, thereby driving a comprehensive upgrade of regional healthcare capacity. According to its plan, Yidu Tech will achieve coverage and management of over 100,000 patients across the region in 2025, injecting strong momentum into improving population health.

医渡科技中标某研究所急性呼吸道感染监测研究 SMO 服务项目

Yidu Tech Wins Bid for SMO Service Project on Acute Respiratory Infection Surveillance Research

该项目是客户方重点推进的高优先级研究项目，医渡科技凭借专业的临床运营服务能力和高效协同的执行方案，在医学、运营等多环节获得客户全面认可，成功达成合作。此次合作不仅体现了公司在呼吸疾病领域临床研究服务的专业实力，也为后续与客户开展更广泛、深入的合作奠定了坚实基础。

This project is a high-priority research initiative strongly advanced by the client. Leveraging its professional clinical operations capabilities and an efficient, well-coordinated execution plan, Yidu Tech earned full recognition from the client across multiple aspects including medical and operational delivery, and successfully secured the collaboration. This partnership not only demonstrates the company's professional strength in providing clinical research services in the field of respiratory diseases but also lays a solid foundation for broader and deeper cooperation with the client in the future.

医渡科技中标国内某知名药企口服保肝药 SMO 服务项目

Yidu Tech Wins SMO Service Project for an Oral Hepatoprotective Drug from a Leading Domestic Pharmaceutical Company

此次合作是医渡科技与该企业的首次合作，标志着双方正式建立合作关系。该项目中，公司凭借专业的临床运营服务能力和灵活的解决方案，获得了客户的高度认可。此次合作也为医渡科技在肝病治疗领域积累了宝贵的项目经验，为未来与客户持续深化合作奠定了良好基础。

This collaboration marks the first partnership between Yidu Tech and the pharmaceutical enterprise, signifying the formal establishment of a cooperative

relationship. In this project, Yidu Tech earned high recognition from the client through its professional clinical operations capabilities and flexible solutions. The cooperation also provides Yidu Tech with valuable project experience in the field of liver disease treatment, laying a solid foundation for deepening collaboration with the client in the future.

医渡科技中标国内某领先细胞治疗企业血液与呼吸领域 SMO 项目

Yidu Tech Wins SMO Service Project in Hematology and Respiratory Fields from a Leading Domestic Cell Therapy Company

基于此前在血液疾病领域细胞制品临床试验 SMO 服务中的卓越表现和客户的高度认可，双方合作关系持续深化，一年内已实现四次复购，并进一步拓展至呼吸及骨科等多个疾病领域。此次合作不仅体现了医渡科技在提供专业化、高质量临床运营服务方面的综合能力，也进一步巩固了公司在细胞治疗临床研究服务领域的战略布局与发展优势。

Building on its outstanding performance and strong client recognition in previous SMO services for cell product clinical trials in hematologic diseases, Yidu Tech has continued to deepen its partnership with the client. Within one year, the collaboration has resulted in four repeat engagements and has further expanded into multiple therapeutic areas, including respiratory and orthopedics. This latest cooperation not only demonstrates Yidu Tech's comprehensive capabilities in delivering professional and high-quality clinical operations services but also further strengthens the company's strategic positioning and competitive advantage in the field of cell therapy clinical research services.

医渡科技中标广东省某三甲医院随机化系统与 EDC 系统本地化部署及多个建库项目

Yidu Tech Wins Bid for Localization Deployment of Randomization and EDC Systems and Multiple Database Projects at a Grade III-A Hospital in Guangdong Province

临床研究中，随机化系统与 EDC 系统是保障研究数据规范采集与高效管理的关键工具。本次合作通过为医院临床研究提供专业化系统部署与数据库建设服务，为其 IIT 研究的规范化、高效化开展提供了坚实的技术支持。该项目实现了医渡科技在广东地区临床研究系统服务领域的新突破，不仅体现了公司在数字化临床研究解决方案方面的技术实力，也为未来双方在 IIT 大包项目等更广泛领域的深入合作奠定了重要基础。

In clinical research, randomization systems and EDC systems are critical tools to ensure standardized data collection and efficient management. Through this collaboration, Yidu Tech is providing the hospital with professional system deployment and database development services, delivering strong technical support for the standardized and efficient advancement of its IITs. This project marks a new breakthrough for Yidu Tech in clinical research system services in Guangdong Province. It not only highlights the company's technological strength in digital clinical research solutions but also lays an important foundation for broader future cooperation between the two parties.

政策利好

Policy Benefits

"人工智能+"重磅政策出炉，医渡科技展现医疗领域全景实践路径

"AI+" Policy Released, Yidu Tech Demonstrates a Comprehensive Practice Path in Healthcare

8 月 26 日，国务院印发《关于深入实施"人工智能+"行动的意见》。《意见》提出加快实施 6 大重点行动，包括"人工智能+"科学技术、"人工智能+"产业发展、"人工智能+"消费提质、"人工智能+"民生福祉、"人工智能+"治理能力、"人工智能+"全球合作。医渡科技从破解医疗科研难题到打通技术落地堵点，从赋能新药研发到守护民生健康，从筑牢公共卫生防线到助力全球医疗合作，每一步实践都与《意见》中"人工智能+"的行动方向深度契合。公司以"政策导向为纲、技术创新为核、场景落地为要"，正以实际行动加速"人工智能+"从政策蓝图转化为现实成果。

On August 26, the State Council issued the Opinions on Deepening the Implementation of the "AI+" Initiative. The document outlines six priority actions: "AI+ Science and Technology," "AI+ Industrial Development," "AI+ Consumption Upgrade," "AI+ Public Well-being," "AI+ Governance Capacity," and "AI+ Global Cooperation." Yidu Tech's initiatives—from tackling medical research challenges to unblocking technology deployment, from empowering new drug R&D to safeguarding public health, and from reinforcing public health defenses to advancing global healthcare collaboration—are fully aligned with the action directions set forth in the Opinions. With a strategic approach of policy guidance as the framework, technological innovation as the core, and scenario implementation as the driver, Yidu Tech is taking concrete actions to accelerate the transformation of the "AI+" blueprint from policy vision into tangible outcomes.

医保商保融合提速：医渡科技实现科技赋能与惠民实践的双向突破

Integration of Public and Private Health Insurance Accelerates: Yidu Tech Achieves Breakthroughs in Both Technology Empowerment and Public Benefit

国家医保局在全国医疗保障工作会议上表示，2025 年将大力推动商业健康保险与基本医保的有效衔接。今年 7 月，全国首个"医保+商保"清分结算中心在北京投入运营，作为国家医保局以医保数据赋能商保发展的试点项目，该中心推动医保商保数据互通。

同月，国家医保局发布公告，首次增设"商业健康保险创新药品目录"，近日已公布首版商保创新药目录通过初审名单。

这一系列举措标志着医保、商保正在加速融合，商业健康险的发展无疑将迎来更大的想象空间。随着新政推行，惠民保作为政策落地的"先行军"，其提质扩面离不开技术经验的持续赋能。医渡科技凭借全链条保险科技能力以及多地惠民保项目运营实践，可以更快地把成熟的技术经验复制到更多地区，助力惠民保进一步扩大参保覆盖面并优化保障体验，让政策红利更精准地覆盖民众需求。

At the National Healthcare Security Work Conference, the National Healthcare Security Administration (NHSA) announced that in 2025 it will vigorously promote the effective integration of commercial health insurance with basic medical insurance. In July, China's first "Public–Private Health Insurance Clearing and Settlement Center" began operations in Beijing. As a pilot project leveraging public insurance data to empower commercial insurance, the center enables data interoperability between public and private insurers. That same month, NHSA issued a notice establishing, for the first time, a "Commercial Health Insurance Innovative Drug List" and recently published the initial shortlist of approved products.

These measures mark the accelerating convergence of public and private health insurance, opening vast growth opportunities for the commercial health insurance sector. With the rollout of these new policies, supplementary insurance—a government-supported inclusive health insurance scheme—has become a key early implementer. Its continued quality improvement and expansion rely on sustained technological enablement. Leveraging its end-to-end insurance technology capabilities and practical experience in operating supplementary insurance projects across multiple regions, Yidu Tech is able to rapidly replicate proven technical expertise to more local markets. This helps expand coverage and enhance the protection experience, ensuring that the benefits of policy innovation more precisely meet the needs of the public.

投资者交流

Investor Communication

医渡科技股东周年大会成功举办

Yidu Tech Successfully Holds 2025 Annual General Meeting

医渡科技于 2025 年 8 月 29 日在北京总部召开了 2025 股东周年大会。股东周年大会由公司执行董事封晓瑛女士主持，并审议和通过了相关决议案。

有关股东周年大会投票表决结果，请参阅刊登在港交所网站的公告。

Yidu Tech convened 2025 Annual General Meeting (AGM) at its Beijing headquarters on August 29, 2025. The AGM was chaired by Feng Xiaoying, Executive Director of the Company, during which the relevant resolutions were reviewed and duly passed. For details of the voting results of the AGM, please refer to the announcement published on the Hong Kong Stock Exchange website.

医渡科技 IRD 出席多家券商策略交流会，与投资者共话 AI 医疗新机遇

Yidu Tech IRD Attends Multiple Securities Firms' Strategy Conferences, Discuss New Opportunities in AI Healthcare

医渡科技投资者关系总监 Helena Wang 近日受邀出席广发证券与华泰证券等多场重磅投资峰会及闭门交流会，与众多知名机构投资者围绕 AI 医疗领域的技术创新、业务发展与战略布局展开深度交流。系列活动中，公司积极参与峰会期间的一对一会谈、小范围闭门会议等多种交流形式，全面介绍医渡科技在医疗人工智能领域的核心竞争优势与最新业务进展。通过详实分享技术落地成果与商业化进程，公司进一步强化了资本市场对其在 AI 医疗赛道价值与增长潜力的认可。此次系列交流有效拓宽了医渡科技与投资机构的沟通渠道，持续提升市场对公司未来发展方向的认知与信心，为长期战略推进凝聚广泛关注与支持。

Yidu Tech's IRD Helena Wang was invited to attend several high-profile investment summits and closed-door meetings organized by GF Securities, Huatai Securities, and others. She held in-depth discussions with prominent institutional investors on technological innovation, business development, and strategic planning in AI healthcare. During the series of events, Yidu Tech provided a comprehensive overview of its core competitive advantages and latest progress in AI medical. By sharing detailed achievements in technology implementation and commercialization, the company further strengthened capital market recognition of its value and growth potential in the AI healthcare sector. These engagements have effectively broadened Yidu Tech's communication channels with investment institutions, enhanced market understanding and confidence in the company's future direction, and garnered strong support for the advancement of its long-term strategy.